These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 9422064)

  • 1. [Tubulin and its related signal].
    Nishio K
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2213-8. PubMed ID: 9422064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoskeletons and antimitotic agents developed in Japan.
    Nishio K; Saijo N
    Anticancer Drug Des; 1999 Apr; 14(2):133-41. PubMed ID: 10405640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
    Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
    Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors.
    Hoshino R; Chatani Y; Yamori T; Tsuruo T; Oka H; Yoshida O; Shimada Y; Ari-i S; Wada H; Fujimoto J; Kohno M
    Oncogene; 1999 Jan; 18(3):813-22. PubMed ID: 9989833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
    Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural organic compounds that affect to microtubule functions.
    Iwasaki S
    Yakugaku Zasshi; 1998 Apr; 118(4):112-26. PubMed ID: 9564789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubule-associated proteins as targets in cancer chemotherapy.
    Bhat KM; Setaluri V
    Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade.
    Desbiens KM; Deschesnes RG; Labrie MM; Desfossés Y; Lambert H; Landry J; Bellmann K
    Biochem J; 2003 Jun; 372(Pt 2):631-41. PubMed ID: 12646044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
    Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors determining cellular mechanisms of resistance to antimitotic drugs.
    Cabral F
    Drug Resist Updat; 2001 Feb; 4(1):3-8. PubMed ID: 11512151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.